LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Smith also points out that the focus on Dato-DXd has overshadowed AstraZeneca’s promising non-oncology pipeline, which is expected to deliver significant developments between 2025 and 2028.

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

While sales of Astra’s oncology drugs were up 10% more than expected in the third quarter, analysts expressed concern about ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...

Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...